Cocrystal Pharma Inc (COCP)

Overview News Price History Discussions Forecast Stock Split

Cocrystal Pharma Inc stock is currently priced at $1.495, with a 24-hour trading volume of 5,066. It has seen a +4.55% increased in the last 24 hours and a +1.01% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.46 pivot point. If it approaches the $1.50 resistance level, significant changes may occur.

Cocrystal Pharma Inc Stock (COCP) Financials Data

Cocrystal Pharma Inc (COCP) Net Income 2024

COCP net income (TTM) was -$18.02 million for the quarter ending September 30, 2023, a +52.60% increase year-over-year.

Cocrystal Pharma Inc (COCP) Cash Flow 2024

COCP recorded a free cash flow (TTM) of -$16.30 million for the quarter ending September 30, 2023, a +16.54% increase year-over-year.

Cocrystal Pharma Inc (COCP) Earnings per Share 2024

COCP earnings per share (TTM) was -$2.00 for the quarter ending September 30, 2023, a +31.97% growth year-over-year.

Cocrystal Pharma Inc Stock (COCP) Latest News

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

GlobeNewswire Inc.

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

GlobeNewswire Inc.

Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

GlobeNewswire Inc.

Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344

GlobeNewswire Inc.

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.